Device Trial Radar · NCT04860986
A Repeatability and Reproducibility Study of the EarliPoint™ Device
Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
May 7, 2021
Primary completion
Nov 17, 2021
Study completion Nov 17, 2021
Sponsor
- Lead sponsor
- EarliTec Diagnostics, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 27, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 16 months, up to 30 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a prospective randomized repeatability and reproducibility (R\&R) study of the EarliPoint DeviceTM in pediatric subjects 16-30 months of age. The study will enroll subjects who are both clinically-positive and clinically-negative for ASD. The study will be conducted at a single center in the US. The Study consists of a screening period in order to review the subject's medical history to determine subject eligibility, followed by a device administration period during which subjects will undergo testing with the EarliPoint Devices and Expert Clinician Diagnosis (ECD) procedures to determine if they are clinically-positive or clinically-negative for ASD.
Conditions
- Autism Spectrum Disorder (ASD)
Interventions
EarliPointDevice
EarliPoint is a non-invasive diagnostic device for ASD
Primary outcomes
What the sponsor says the trial is designed to measure.
- The EarliPoint Device repeatabilityTime frame: Anticipated in about 6 months
- The EarliPoint Device reproducibilityTime frame: Anticipated in about 6 months
- The repeatability variance of the underlying EarliPoint DeviceTime frame: Anticipated in about 6 months
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.